Epistem licence Hubrecht Organoid Technology to expand pre-clinical toxicology service portfolio
MANCHESTER, United Kingdom, July 16, 2019 (GLOBE NEWSWIRE) -- Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB) to enable the delivery of an increased range of multi species organoid models. Services are focused on the identification of off target or off tissue intestinal toxicities associated with various therapeutics. Specifically, Epistem aims to help customers define whether there are reasons to suspect that there may be human toxicity issues. This will allow better prioritisation of lead compounds, with customers able to make early decisions on whether to abandon, identify alternatives, or develop mitigation strategies for any drugs with human toxicity.
Organoids are adult stem cell patient or animal derived structures. Organoids are genetically stable and maintain epithelial functionality in the laboratory. The expanding stem cells generate all epithelial cell types and self organise to produce structures that are a simplified replicas of the organ from which they were derived. This enables the effects of new drugs to be evaluated in a relatively quick, yet highly controlled (and hence robust) manner.
Dr. Benjamin Reed, Commercial Director, Epistem, commented, “I am delighted to add further services to our existing repertoire of 3D culture models. We are committed to provide innovative services to accelerate drug development. Organoids will be a key addition to our portfolio of services and will enable our customers identify toxicity issues using a model that is indicative of the outcome when dosing animals and humans.”
Dr. Catherine Booth, CEO, Epistem, added, “Organoids provide valuable insight into toxicity when analyzed using techniques such as gene expression profiling, imaging and FACs analysis. They will help, alongside well designed in vivo studies, enable our customers to make more informed decisions and improve the efficiency of their drug development process. We are also developing complementary services to investigate drug and microbiota effects on barrier function, inflammatory signals and early fibrosis.”
Dr. Bahar Ramezanpour, Head of Business Development, HUB, commented, “We are happy to announce this partnership with one of the leading preclinical research service providers. Epistem’s services will help expand our toxicology services to support pharmaceutical and biotech companies identify early stage toxicity issues with new compounds.”
Notes for editors
About Epistem Ltd
Epistem is an established research service provider with headquarters in Manchester UK. Founded on ground-breaking research in epithelial stem cell biology, Epistem has evolved into a dynamic and successful business that provides innovative research services. For 19 years Epistem has been providing a personalised service to customers worldwide, from virtual start-ups to established biotechnology companies, global pharmaceutical and personal care companies. Epistem is committed to providing reliable, innovative and transferable pre-clinical and clinical models and services to support decision making throughout the drug discovery and development pipeline. More info at www.epistem.co.uk
Hubrecht Organoid Technology (HUB) is an organization founded by the Royal Netherlands Academy of Sciences and the University Medical Center Utrecht. HUB exploits the pioneering work of Prof. Hans Clevers, who discovered methods to grow stem cell-derived human ‘mini-organs’ (HUB Organoids) from tissues of patients with various diseases. The organoids, which are part of the HUB biobanks, are characterized by genome sequencing, expression profiling and sensitivity to known and experimental drugs to establish a database linking genetic and transcriptional information to drug responsiveness. HUB offers licenses to its patented HUB Organoid Technology and access to organoids from the HUB biobank for preclinical drug screening, discovery, development and validation. In addition, HUB is performing clinical studies to validate the technology’s use as a companion diagnostic. More info at www.hub4organoids.eu.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Stephanie Werner appointed Chief Human Resources Officer and a member of the Nokia Group Leadership team as Hans-Jürgen Bill retires 12.12.2019 08:30:00 CET | Press release
Nokia Corporation Stock Exchange Release December 12, 2019 at 9.30 (CET +1) Stephanie Werner appointed Chief Human Resources Officer and a member of the Nokia Group Leadership team as Hans-Jürgen Bill retires Espoo, Finland – Nokia today announced the appointment of Stephanie Werner, as Chief Human Resources Officer, effective January 1, 2020. Hans-Jürgen Bill, Nokia’s current Chief Human Resources Officer, will retire in May 2020. Stephanie Werner has been with Nokia since 1998 and has held various HR leadership positions in countries including China, Switzerland, Philippines, USA and Romania. She will be based in Finland. “I am pleased to be able to welcome Stephanie to take the lead on our people strategy during a critical time for Nokia,” said Rajeev Suri, President and Chief Executive Officer of Nokia. “She will play a key role in enabling our ongoing transformation and building a high-performance culture. I want to thank Hans-Jürgen for his many contributions to Nokia and wish hi
Aino Health AB (publ): Aino Health tecknar avtal med Centric Sverige gällande SaaS-lösningen HealthManager12.12.2019 08:25:00 CET | Pressemelding
Aino Health hat tecknat ett avtal, gällande SaaS-lösningen HealthManager, med Centric – ett It-företag som erbjuder konsulttjänster och IT outsourcing. Avtalet löper initialt över två år. I den första fasen kommer HealthManager att implementeras för ca 350 personer i Sverige, av de totalt 800 personer som är anställda i Norden. Centric har totalt 4500 anställda i Europa fördelat på 7 olika länder. Centric har letat efter en lösning som kan hjälpa dem att arbeta mer effektivt och strukturerat när det gäller de anställdas välmående och hälsa och som samtidigt kan stötta cheferna arbetssätt gällande detta. Målen med implementationen är högre närvaro och välmående hos de anställda. Projektets första fas är planerad att vara implementerad i december i år. HealthManager är en SaaS plattform som stöttar chefer med intern hälsorelaterade processer och frånvarohantering. kommunikation och engagemang. Tjänsten erbjuder verktyg för rapportering och analys för att följa nyckeltal kopplade till Cor
Aino Health AB (publ): Aino Health signs agreement with Centric Sweden regarding the SaaS solution HealthManager12.12.2019 08:25:00 CET | Press release
Aino Health has signed an agreement, regarding the SaaS solution HealthManager, with Centric - an IT company offering consultants as well as IT outsourcing. The initial agreement is a two-year contract. In the first phase, HealthManager will be implemented for around 350 persons in Sweden out of the in total about 800 Centric employees in the Nordics. In Europe, Centric has more than 4500 employees in 7 countries. Centric has been looking for a solution that can help them to work in a more structural and efficient way regarding employee wellbeing and health, and at the same time support the managers’ way of working with this. The goals are to increase presence at work and the wellbeing of the personnel. The first phase of the project is projected to be live in December this year. HealthManager is a SaaS solution that supports managers with internal health-related processes and absence management. It also offers reporting and analytic tools to follow key metrics related to corporate hea
Nokia wins Deutsche Bahn tender to deliver and test the world’s first 5G-based network for automated rail operation12.12.2019 08:15:00 CET | Press release
Press Release The solution is one of the world’s first standalone 5G networks used for automated rail operation. The project constitutes an essential milestone in the development of the 5G-based Future Railway Mobile Communication System (FRMCS) standard — the successor to the current GSM-R standard 12 December 2019 Espoo, Finland – Nokia has won a tender to test and deliver the world’s first standalone (SA) 5G system for automated rail operation in Hamburg, Germany. The project is part of Deutsche Bahn’s highly automated S-Bahn operation project. The proof-of-concept will test whether 5G technology is mature enough to be used as the connectivity layer for future, digitalized rail operations. The project constitutes an early and important step in the development of the Future Railway Mobile Communications System (FRMCS) standard, based on 5G, and sets the stage for the digital transformation of railway operations. Nokia is a leader in this market with extensive experience in providing
PRF: Change in the management board of Osaühing Vettel12.12.2019 08:09:00 CET | Press release
Dagni Viskus was elected as a management board member of Osaühing Vettel (subsidiary of AS PRFoods) being responsible for production management in Saaremaa. Dagni Viskus was previously working in Osaühing Vettel as a quality manager. Dagni Viskus has no shares of AS PRFoods. Besides Dagni Viskus, Indrek Kasela and Jarkko Tapani Alho are members of the management board of Osaühing Vettel. Indrek Kasela AS PRFoods Member of the Management Board Phone: +372 452 1470 email@example.com www.prfoods.ee
SpareBank 1 SMN: Mandatory notification of trade – SpareBank 1 SMN’s savings programme allocates equity certificates12.12.2019 08:08:00 CET | Press release
SpareBank 1 SMN – Mandatory notification of trade – SpareBank 1 SMN’s savings programme allocates equity certificates The equity certificates purchased by SpareBank 1 SMN on 6 and 9 December 2019 for use in the group’s savings programme for employees, have been distributed to the employees at a price of NOK 97.78 per equity certificate in accordance with their savings amount. Following this, the savings programme has 704,242 equity certificates. After allocation the bank owns 625 equity certificates. As participants in the savings programme, the primary insiders below have been allocated equity certificates as follows: Name: Allocated no. equity certificates: New total holding of equity certificates*: Cathrine Aunvik 63 1,461 Rolf Jarle Brøske 63 7,134 Tomm Bøyesen 63 5,823 Kjell Fordal 63 245,883 Vegard Helland 63 34,773 Kjersti Hønstad 63 4,485 Inge Lindseth 63 4,034 Nelly Maske 63 20,854 Ola Neråsen 63 42,335 Margrethe L. Resellmo 17 398 Berit Rustad 63 3,546 Camilla Stang 17 398 Ch